Literature DB >> 22573859

Refined identification of neutralization-resistant HIV-1 CRF02_AG viruses.

Rajesh Abraham Jacob1, Fatima Abrahams, Marcel Tongo, Michael Schomaker, Paul Roux, Eitel Mpoudi Ngole, Wendy A Burgers, Jeffrey R Dorfman.   

Abstract

We studied neutralization of CRF02_AG HIV-1-infected plasma samples. In contrast to previous reports, these samples neutralized CRF02_AG viruses better than other viruses. This included six of eight CRF02_AG viruses previously designated resistant (tier 2/3 or 3). Only viruses 253-11 and 278-50 remained highly resistant, but they were sensitive to membrane-proximal external region (MPER)-specific monoclonal antibodies, suggesting neutralization targets for even these viruses. We propose using high-neutralizing-within-subtype samples for evaluation of neutralization resistance of viruses.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22573859      PMCID： PMC3416284          DOI： 10.1128/JVI.00804-12

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  48 in total

1.  Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.

Authors:  E O Saphire; P W Parren; R Pantophlet; M B Zwick; G M Morris; P M Rudd; R A Dwek; R L Stanfield; D R Burton; I A Wilson
Journal:  Science       Date:  2001-08-10       Impact factor: 47.728

Review 2.  Antibody protection: passive immunization of neonates against oral AIDS virus challenge.

Authors:  Ruth M Ruprecht; Flavia Ferrantelli; Moiz Kitabwalla; Weidong Xu; Harold M McClure
Journal:  Vaccine       Date:  2003-07-28       Impact factor: 3.641

Review 3.  Passive immunization with human neutralizing monoclonal antibodies: correlates of protective immunity against HIV.

Authors:  Weidong Xu; Regina Hofmann-Lehmann; Harold M McClure; Ruth M Ruprecht
Journal:  Vaccine       Date:  2002-05-06       Impact factor: 3.641

4.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

5.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection.

Authors:  Douglas D Richman; Terri Wrin; Susan J Little; Christos J Petropoulos
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-18       Impact factor: 11.205

6.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.

Authors:  T Muster; F Steindl; M Purtscher; A Trkola; A Klima; G Himmler; F Rüker; H Katinger
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

7.  Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.

Authors:  D R Burton; J Pyati; R Koduri; S J Sharp; G B Thornton; P W Parren; L S Sawyer; R M Hendry; N Dunlop; P L Nara
Journal:  Science       Date:  1994-11-11       Impact factor: 47.728

8.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

9.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

Authors:  A Trkola; M Purtscher; T Muster; C Ballaun; A Buchacher; N Sullivan; K Srinivasan; J Sodroski; J P Moore; H Katinger
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.

Authors:  A Buchacher; R Predl; K Strutzenberger; W Steinfellner; A Trkola; M Purtscher; G Gruber; C Tauer; F Steindl; A Jungbauer
Journal:  AIDS Res Hum Retroviruses       Date:  1994-04       Impact factor: 2.205
View more
  4 in total

1.  Sensitivity to Broadly Neutralizing Antibodies of Recently Transmitted HIV-1 Clade CRF02_AG Viruses with a Focus on Evolution over Time.

Authors:  Karl Stefic; Mélanie Bouvin-Pley; Asma Essat; Clara Visdeloup; Alain Moreau; Cécile Goujard; Marie-Laure Chaix; Martine Braibant; Laurence Meyer; Francis Barin
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

2.  Neutralizing Antibody Response and Antibody-Dependent Cellular Cytotoxicity in HIV-1-Infected Individuals from Guinea-Bissau and Denmark.

Authors:  Marie Borggren; Sanne Skov Jensen; Leo Heyndrickx; Angelica A Palm; Jan Gerstoft; Gitte Kronborg; Bo Langhoff Hønge; Sanne Jespersen; Zacarias José da Silva; Ingrid Karlsson; Anders Fomsgaard
Journal:  AIDS Res Hum Retroviruses       Date:  2016-01-07       Impact factor: 2.205

3.  Anti-V3/Glycan and Anti-MPER Neutralizing Antibodies, but Not Anti-V2/Glycan Site Antibodies, Are Strongly Associated with Greater Anti-HIV-1 Neutralization Breadth and Potency.

Authors:  Rajesh Abraham Jacob; Thandeka Moyo; Michael Schomaker; Fatima Abrahams; Berta Grau Pujol; Jeffrey R Dorfman
Journal:  J Virol       Date:  2015-02-11       Impact factor: 5.103

4.  Molecular Basis of Unusually High Neutralization Resistance in Tier 3 HIV-1 Strain 253-11.

Authors:  Thandeka Moyo; June Ereño-Orbea; Rajesh Abraham Jacob; Clara E Pavillet; Samuel Mundia Kariuki; Emily N Tangie; Jean-Philippe Julien; Jeffrey R Dorfman
Journal:  J Virol       Date:  2018-06-29       Impact factor: 5.103
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.